cdc-coteauxdegaronne
» » Novel Targeted Drugs for the Treatment of Lymphoma: The Biological Basis for Innovative Drug Discovery and Development (Contemporary Hematology)
eBook Novel Targeted Drugs for the Treatment of Lymphoma: The Biological Basis for Innovative Drug Discovery and Development (Contemporary Hematology) ePub

eBook Novel Targeted Drugs for the Treatment of Lymphoma: The Biological Basis for Innovative Drug Discovery and Development (Contemporary Hematology) ePub

by Owen A. O'Connor,Jennifer E. Amengual,John Gerecitano

  • ISBN: 1588299325
  • Category: Medicine and Health Sciences
  • Subcategory: Other
  • Author: Owen A. O'Connor,Jennifer E. Amengual,John Gerecitano
  • Language: English
  • Publisher: Humana Press; 1st ed. 2019 edition (May 11, 2019)
  • Pages: 400
  • ePub book: 1840 kb
  • Fb2 book: 1328 kb
  • Other: azw mbr rtf lrf
  • Rating: 4.1
  • Votes: 295

Description

Over the past decade, there has been an explosion in the number of new drugs being developed for the treatment of cancer. This has become particularly true in the case of lymphoma.

price for USA in USD (gross). Due: August 11, 2020. ISBN 978-1-59745-286-1. Over the past decade, there has been an explosion in the number of new drugs being developed for the treatment of cancer. However, what frequently remains unclear to many is that this increase in new agents, and the often novel targets they affect, is a direct product of our never ending quest to understand the fundamentals of cancer cell biology.

by Owen A. O'Connor/ Jennifer E. Amengual/John Gerecitano · data of the book . Novel Targeted Drugs for the Treatment of Lymphoma: The Biological Basis for Innovative Drug Discovery and Development (Contemporary Hematology)

by Owen A. Amengual/John Gerecitano · data of the book Novel Targeted Drugs for the. Novel Targeted Drugs for the Treatment of Lymphoma: The Biological Basis for Innovative Drug Discovery and Development (Contemporary Hematology). by: Owen A. O'Connor · Jennifer E. Amengual · John Gerecitano.

Drug Discovery and Development: Technology in Transition. Provides an introduction to the drug discovery process from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual property.

Non-biological Complex Drugs (NBCDs) are medical compounds that cannot be defined as small molecular, fully identifiable drugs with active pharmaceutical ingredients. They are highly complex and cannot be defined as biologicals as they are not derived from living materials. NBCDs are synthetic complex compounds and they contain non-homomolecular, closely related molecular structures with often nanoparticular properties. This is, for instance, the case with the iron sucrose and its similars.

2019 The Biological Basis for Innovative Drug Discovery and Development Contemporary Hematology . Over the past decade, there has been an explosion in the number of new drugs being developed for the treatment of cancer

2019 The Biological Basis for Innovative Drug Discovery and Development Contemporary Hematology Series. Coordinators: O'Connor Owen . Amengual Jennifer . Gerecitano John.

Drug-target interactions play an important role for biomedical drug discovery and development. Therefore, developing computational techniques for drug-target interaction prediction is urgent and has practical significance. However, it is expensive and time-consuming to accomplish this task by experimental determination. In this work, we propose an effective computational model of dual Laplacian graph regularized matrix completion, referred to as DLGRMC briefly, to infer the unknown drug-target interactions.

Books related to Anti-Angiogenesis Drug Discovery and Development Volume: . Immunomodulating Drugs for the Treatment of Cancer. Combining Targeted Biological Agents with Radiotherapy.

Books related to Anti-Angiogenesis Drug Discovery and Development Volume: 3. Skip this list.

Owen O'Connor, MD, PhD specializes in Hematology, Lymphoma, Cancer Care at ColumbiaDoctors in New York City

Owen O'Connor, MD, PhD specializes in Hematology, Lymphoma, Cancer Care at ColumbiaDoctors in New York City. To date, he has pioneered the development of three new drugs approved for the treatment of lymphoma, and collaborated with national and international colleagues on many others. Working in collaboration with the National Cancer Institute (NCI), he was the first to identify the activity of bortezomib (Velcade), a novel class of drugs targeting the proteasome, in patients with relapsed or refractory mantle cell lymphoma, which eventually led to bortezomib becoming the first drug approved by the . Food and Drug Administration for this disease in. 2006.

Owen A. O’Connor, MD, P. . Dr. O’Connor is a Professor of Medicine and Experimental Therapeutics, and the Director of the Center for Lymphoid Malignancies, and Co-Program Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.

Keywords: CLL, HCL, prolymphocytic leukemia, purine nucleoside ananalogs, oblimersen, flavopiridol, bryostatin 1, lenalidomide, monoclonal antibodies.

Over the past decade, there has been an explosion in the number of new drugs being developed for the treatment of cancer. This has become particularly true in the case of lymphoma. However, what frequently remains unclear to many is that this increase in new agents, and the often novel targets they affect, is a direct product of our never ending quest to understand the fundamentals of cancer cell biology. Targeting these unique pathogenetic mechanisms is the most attractive strategy for altering the natural history of any malignancy, and the pace at which we are clarifying this biology is truly daunting.

One of the primary goals of Novel Targeted Drugs for the Treatment of Lymphoma is to emphasize this new biology, allowing it it become the cornerstone for understanding how and why these novel agents are moving rapidly into the mainstream of patient care. Each section starts with a comprehensive chapter on the important aspects of the relevant biology, written by an authority in that field. Subsequent chapters focus on discrete agents, and how they establish the 'proof of principle'. Every effort is made to present a fair and unbiased account of those agents, with particular attention being paid to those compounds that appear the most differentiated. Well organized and easy to read, this book is a valuable resource for all practitioners in the field.